GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity.

Kadouh H, Chedid V, Halawi H, Burton DD, Clark MM, Khemani D, Vella A, Acosta A, Camilleri M

The Journal of clinical endocrinology and metabolism1 May 2020Cited by 125 (Europe PMC)

PMID31665455PMCIDPMC7105351DOI10.1210/clinem/dgz140PepBankPUB-31665455

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. 14 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with obesity, liraglutide reduced maximal tolerated volume in a nutrient drink test versus placebo.
In plain wordsIn adults with obesity, liraglutide reduced how much people could drink in a nutrient test compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseMaximal tolerated volume
Study
n = 35
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
3 mg daily (escalated) · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
Compared to placebo group, liraglutide group had significant reductions in MTV; prospective food consumption score; desire to eat something sweet, salty, savory or fatty; and an increase in perceived fullness.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty obese adults received standard instruction for weight management, monthly behavioral intervention utilizing motivational interviews, and 16-week treatment of once-daily liraglutide (escalated to 3 mg SQ daily).
Summary · context
Thirty-five participants (17 liraglutide; 18 placebo) completed the trial.
Report a problemFND-3166545501
02HumanRandomized controlled trialEfficacy outcome
In adults with obesity, liraglutide reduced the prospective food consumption score versus placebo.
In plain wordsIn adults with obesity, liraglutide lowered the amount of food people expected to eat compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseProspective food consumption score
Study
n = 35
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
3 mg daily (escalated) · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
Compared to placebo group, liraglutide group had significant reductions in MTV; prospective food consumption score; desire to eat something sweet, salty, savory or fatty; and an increase in perceived fullness.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty obese adults received standard instruction for weight management, monthly behavioral intervention utilizing motivational interviews, and 16-week treatment of once-daily liraglutide (escalated to 3 mg SQ daily).
Summary · context
Thirty-five participants (17 liraglutide; 18 placebo) completed the trial.
Report a problemFND-3166545502
03HumanRandomized controlled trialEfficacy outcome
In adults with obesity, liraglutide reduced the desire to eat something sweet versus placebo.
In plain wordsIn adults with obesity, liraglutide lowered the wish to eat sweet food compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseDesire to eat something sweet
Study
n = 35
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
3 mg daily (escalated) · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
Compared to placebo group, liraglutide group had significant reductions in MTV; prospective food consumption score; desire to eat something sweet, salty, savory or fatty; and an increase in perceived fullness.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty obese adults received standard instruction for weight management, monthly behavioral intervention utilizing motivational interviews, and 16-week treatment of once-daily liraglutide (escalated to 3 mg SQ daily).
Summary · context
Thirty-five participants (17 liraglutide; 18 placebo) completed the trial.
Report a problemFND-3166545503
04HumanRandomized controlled trialEfficacy outcome
In adults with obesity, liraglutide reduced the desire to eat something salty versus placebo.
In plain wordsIn adults with obesity, liraglutide lowered the wish to eat salty food compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseDesire to eat something salty
Study
n = 35
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
3 mg daily (escalated) · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
Compared to placebo group, liraglutide group had significant reductions in MTV; prospective food consumption score; desire to eat something sweet, salty, savory or fatty; and an increase in perceived fullness.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty obese adults received standard instruction for weight management, monthly behavioral intervention utilizing motivational interviews, and 16-week treatment of once-daily liraglutide (escalated to 3 mg SQ daily).
Summary · context
Thirty-five participants (17 liraglutide; 18 placebo) completed the trial.
Report a problemFND-3166545504
05HumanRandomized controlled trialEfficacy outcome
In adults with obesity, liraglutide reduced the desire to eat something savory versus placebo.
In plain wordsIn adults with obesity, liraglutide lowered the wish to eat savory food compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseDesire to eat something savory
Study
n = 35
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
3 mg daily (escalated) · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
Compared to placebo group, liraglutide group had significant reductions in MTV; prospective food consumption score; desire to eat something sweet, salty, savory or fatty; and an increase in perceived fullness.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty obese adults received standard instruction for weight management, monthly behavioral intervention utilizing motivational interviews, and 16-week treatment of once-daily liraglutide (escalated to 3 mg SQ daily).
Summary · context
Thirty-five participants (17 liraglutide; 18 placebo) completed the trial.
Report a problemFND-3166545505
06HumanRandomized controlled trialEfficacy outcome
In adults with obesity, liraglutide reduced the desire to eat something fatty versus placebo.
In plain wordsIn adults with obesity, liraglutide lowered the wish to eat fatty food compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseDesire to eat something fatty
Study
n = 35
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
3 mg daily (escalated) · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
Compared to placebo group, liraglutide group had significant reductions in MTV; prospective food consumption score; desire to eat something sweet, salty, savory or fatty; and an increase in perceived fullness.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty obese adults received standard instruction for weight management, monthly behavioral intervention utilizing motivational interviews, and 16-week treatment of once-daily liraglutide (escalated to 3 mg SQ daily).
Summary · context
Thirty-five participants (17 liraglutide; 18 placebo) completed the trial.
Report a problemFND-3166545506
07HumanRandomized controlled trialEfficacy outcome
In adults with obesity, liraglutide increased perceived fullness versus placebo.
In plain wordsIn adults with obesity, liraglutide increased the feeling of fullness compared with placebo.
Peptide
Liraglutide
Outcome
IncreasePerceived fullness
Study
n = 35
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
3 mg daily (escalated) · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
Compared to placebo group, liraglutide group had significant reductions in MTV; prospective food consumption score; desire to eat something sweet, salty, savory or fatty; and an increase in perceived fullness.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty obese adults received standard instruction for weight management, monthly behavioral intervention utilizing motivational interviews, and 16-week treatment of once-daily liraglutide (escalated to 3 mg SQ daily).
Summary · context
Thirty-five participants (17 liraglutide; 18 placebo) completed the trial.
Report a problemFND-3166545507
08HumanRandomized controlled trialMechanism
In adults with obesity, postprandial plasma GLP-1 levels decreased with liraglutide relative to baseline.
In plain wordsIn adults with obesity, natural GLP-1 levels after meals fell from baseline with liraglutide.
Peptide
Liraglutide
Outcome
DecreasePostprandial plasma GLP-1
Study
n = 35
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
3 mg daily (escalated) · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
Postprandial plasma levels of GLP-1 decreased and PYY levels increased with liraglutide
2 context sentences(design, population, supporting numbers)
Summary · context
Forty obese adults received standard instruction for weight management, monthly behavioral intervention utilizing motivational interviews, and 16-week treatment of once-daily liraglutide (escalated to 3 mg SQ daily).
Summary · context
Thirty-five participants (17 liraglutide; 18 placebo) completed the trial.
Report a problemFND-3166545508
09HumanRandomized controlled trialMechanism
In adults with obesity, postprandial plasma PYY levels increased with liraglutide relative to baseline.
In plain wordsIn adults with obesity, natural PYY levels after meals rose from baseline with liraglutide.
Peptide
Liraglutide
Outcome
IncreasePostprandial plasma PYY
Study
n = 35
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
3 mg daily (escalated) · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
PYY levels increased with liraglutide relative to baseline.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty obese adults received standard instruction for weight management, monthly behavioral intervention utilizing motivational interviews, and 16-week treatment of once-daily liraglutide (escalated to 3 mg SQ daily).
Summary · context
Thirty-five participants (17 liraglutide; 18 placebo) completed the trial.
Report a problemFND-3166545509
10HumanRandomized controlled trialEfficacy outcome
In adults with obesity, liraglutide significantly reduced total body fat.
In plain wordsIn adults with obesity, liraglutide treatment came with a significant reduction in total body fat.
Peptide
Liraglutide
Outcome
DecreaseTotal body fat
Study
n = 35
Outcome group
Body weight · Metabolic and weight
Studied dose
3 mg daily (escalated) · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
Significant reductions in total body, trunk, and upper and lower body fat without reduction in lean body mass were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty obese adults received standard instruction for weight management, monthly behavioral intervention utilizing motivational interviews, and 16-week treatment of once-daily liraglutide (escalated to 3 mg SQ daily).
Summary · context
Thirty-five participants (17 liraglutide; 18 placebo) completed the trial.
Report a problemFND-3166545510
11HumanRandomized controlled trialEfficacy outcome
In adults with obesity, liraglutide significantly reduced trunk fat.
In plain wordsIn adults with obesity, liraglutide treatment came with a significant reduction in trunk fat.
Peptide
Liraglutide
Outcome
DecreaseTrunk fat
Study
n = 35
Outcome group
Body weight · Metabolic and weight
Studied dose
3 mg daily (escalated) · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
Significant reductions in total body, trunk, and upper and lower body fat without reduction in lean body mass were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty obese adults received standard instruction for weight management, monthly behavioral intervention utilizing motivational interviews, and 16-week treatment of once-daily liraglutide (escalated to 3 mg SQ daily).
Summary · context
Thirty-five participants (17 liraglutide; 18 placebo) completed the trial.
Report a problemFND-3166545511
12HumanRandomized controlled trialEfficacy outcome
In adults with obesity, liraglutide significantly reduced upper body fat.
In plain wordsIn adults with obesity, liraglutide treatment came with a significant reduction in upper body fat.
Peptide
Liraglutide
Outcome
DecreaseUpper body fat
Study
n = 35
Outcome group
Body weight · Metabolic and weight
Studied dose
3 mg daily (escalated) · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
Significant reductions in total body, trunk, and upper and lower body fat without reduction in lean body mass were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty obese adults received standard instruction for weight management, monthly behavioral intervention utilizing motivational interviews, and 16-week treatment of once-daily liraglutide (escalated to 3 mg SQ daily).
Summary · context
Thirty-five participants (17 liraglutide; 18 placebo) completed the trial.
Report a problemFND-3166545512
13HumanRandomized controlled trialEfficacy outcome
In adults with obesity, liraglutide significantly reduced lower body fat.
In plain wordsIn adults with obesity, liraglutide treatment came with a significant reduction in lower body fat.
Peptide
Liraglutide
Outcome
DecreaseLower body fat
Study
n = 35
Outcome group
Body weight · Metabolic and weight
Studied dose
3 mg daily (escalated) · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
Significant reductions in total body, trunk, and upper and lower body fat without reduction in lean body mass were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty obese adults received standard instruction for weight management, monthly behavioral intervention utilizing motivational interviews, and 16-week treatment of once-daily liraglutide (escalated to 3 mg SQ daily).
Summary · context
Thirty-five participants (17 liraglutide; 18 placebo) completed the trial.
Report a problemFND-3166545513
14HumanRandomized controlled trialEfficacy outcome
In adults with obesity, liraglutide did not reduce lean body mass.
In plain wordsIn adults with obesity, lean body mass did not fall with liraglutide.
Peptide
Liraglutide
Outcome
No significant changeLean body mass
Study
n = 35
Outcome group
Body weight · Metabolic and weight
Studied dose
3 mg daily (escalated) · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
Significant reductions in total body, trunk, and upper and lower body fat without reduction in lean body mass were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty obese adults received standard instruction for weight management, monthly behavioral intervention utilizing motivational interviews, and 16-week treatment of once-daily liraglutide (escalated to 3 mg SQ daily).
Summary · context
Thirty-five participants (17 liraglutide; 18 placebo) completed the trial.
Report a problemFND-3166545514

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT02647944

Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity

Mayo Clinicn = 4018 Dec 2015 to 30 Dec 2016

Obesity

Trial page ClinicalTrials.govUpdated 27 Oct 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.